Jason B. Fleming, M.D.
Our team has developed patient-derived tissue xenografts (PDX) and numerous related reagents that recapitulate the tumor microenvironment, currently shared with more than 40 laboratories around the world. Throughout the study of extracellular matrix proteins, we found lumican, a small leucine-rich proteoglycan that plays a critical role in of pancreatic ductal adenocarcinoma (PDAC). In addition, our team has developed a first-in-kind preclinical therapeutic tissue platform for drug discovery and repurposing, and personalized precision medicine.
Eugene J. Koay, M.D., Ph.D.
Our group studies the influence of physical properties of malignant hepatobiliary/pancreatic tumors in their biological behavior and response to therapy, by establishing quantitative methods to analyze the diagnostic images and relate this to the underlying pathology of pancreatic cancers. We found associations with multiple clinically relevant endpoints (i.e. delivery of, response to, and outcome) after chemotherapy and radiation. Ongoing work is addressed towards establishing biophysical markers from these imaging-properties to individualize cancer therapy for patients
Xinqun Li, M,D., Ph.D.
My current research interests focuses on investigating novel cell signaling molecules and pathways that may lead to identification and validation of new targets or new co-targeting strategies for developing innovative cancer treatment.
Bingbing Dai, Ph.D.
My efforts have been focusing on developing ex vivo-based methods, including Live Tissue Sensitivity Assay (LTSA) and tumor organoids culture, to facilitate personalized cancer treatment design and investigating new cancer therapeutics. I have also been working on developing novel biomarker-guided combination approaches to pancreatic cancer therapy through functional drug combination screening.
My research focus has been towards the development of advancements strategies for the identification of the best therapy, which include: drug repourposing, translational mouse models of pancreatic cancer (i.e. three dimensional ultrasound imaging; orthotopic PDX models), and LTSA. I collaborate with other groups studying: tumor metabolism, imaging features and biomarkers discovery, by using our patient-derived xenograft reagents.